Ultralife Corporation (NASDAQ: ULBI) — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; comparisons are with FY2019. Unless stated otherwise, amounts below are in USD millions (the filing reports dollar amounts in thousands).
Business context
Ultralife designs and manufactures battery and energy products and military communications systems for commercial, government and defense customers worldwide. Its two segments are Battery & Energy Products and Communications Systems. This is an annual report, not a separate fourth-quarter results filing.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $107.712 | $106.795 |
| Gross profit / margin | $29.159 / 27.1% | $31.165 / 29.2% |
| Operating income | $5.701 | $7.368 |
| Net income attributable to Ultralife | $5.232 | $5.205 |
| Diluted EPS | $0.33 | $0.32 |
| Adjusted EBITDA (non-GAAP) | $9.696 | $11.007 |
| Cash provided by (used in) operating activities | $21.720 | ($2.970) |
| Cash and restricted cash at year-end | $10.653 | $7.405 |
| Debt at year-end | $1.474 | $17.316 |
| Working capital / current ratio | $45.790 / 3.4 | $53.183 / 4.1 |
Battery & Energy Products revenue was $91.907 million, up 9.4%, with segment gross profit of $23.400 million and a 25.5% margin. Communications Systems revenue was $15.805 million, down 30.7%, with segment gross profit of $5.759 million and a 36.4% margin. The filing presents segment results at the gross-profit level.
Material changes versus FY2019
- Total revenue rose 0.9%, but gross profit fell $2.006 million and gross margin contracted 210 basis points. Management attributed the decline mainly to new-product production transition costs and COVID-related disruption, partly offset by improved production efficiency on vehicle amplifier-adaptor systems.
- Medical battery sales increased $13.380 million, supported by demand for products used in ventilators, respirators and infusion pumps. This was partly offset by lower oil-and-gas sales and declines in other commercial industrial markets.
- Communications Systems revenue declined as significant 2019 defense-contract shipments rolled off. Year-end backlog fell 7.7% to $39.292 million; segment backlog was $34.602 million for Battery & Energy Products and $4.690 million for Communications Systems.
- Operating cash flow improved by $24.690 million, substantially reflecting a $12.667 million reduction in net working capital, including collections of receivables from prior-year defense shipments. Investing cash outflow was $2.981 million, mainly capital expenditure.
- Debt declined by $15.842 million. The company repaid its revolving-credit balance and reduced term-loan principal; it reported compliance with credit covenants.
Outlook, commentary and risks
- Management provided no specific revenue or earnings guidance. It said end-market demand visibility remained limited and emphasized organic growth, new-product development, strategic capital investment and synergistic acquisitions. It expected future R&D spending could rise 10% or more above FY2020 levels based on current projects.
- Management estimated COVID-19 reduced FY2020 sales by approximately $7.0 million, operating income by $2.6 million and net income by $2.0 million, or $0.12 per diluted share. Increased medical demand partly offset supply-chain disruption, lower oil-and-gas and international industrial sales, and a roughly one-month mandated closure of the China facility.
- Key exposures include reliance on defense customers and government spending, customer concentration (two customers represented 17% and 6% of revenue), China operations and trade restrictions, oil-and-gas cyclicality, sole- or limited-source components, lithium-battery safety, foreign exchange, and the uncertain duration and effects of COVID-19.
- FY2020 income included a $1.593 million net gain from a finalized lithium-ion battery antitrust class-action settlement. This non-recurring item helped lift pretax income despite lower operating income. The company also reported no goodwill or indefinite-lived intangible impairment in its annual test.
- Liquidity was supported by year-end cash and low debt. Management expected operating cash flow and revolving-credit availability to be sufficient for obligations and planned investment. The filing reports no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether medical-battery demand persists and whether delayed elective-procedure orders recover, given the pandemic-driven nature of some 2020 demand.
- Execution and timing of new products moving into higher-volume production, and the expected increase in R&D spending.
- Conversion of backlog and the timing and actual order volumes under the Defense Logistics Agency awards; maximum contract values are not guaranteed purchases.
- Sustainability of operating cash flow, particularly the extent to which 2020’s improvement depended on working-capital releases and receivable collections.
- Customer concentration, defense-budget exposure, China and supplier risks, and the company’s ability to maintain margins as product mix and input costs change.
- Reconciliation of non-GAAP adjusted EBITDA and adjusted EPS to GAAP results; adjusted EPS excludes deferred tax provision, and the litigation gain is a one-time benefit.